The Union Budget 2026-27, which is currently being presented by the Union Finance Minister Nirmala Sitharaman, has announced significant measures to promote the biopharma sector in the country.
The Nifty Pharma index added 0.51% to 21,824.80 while the benchmark Nifty 50 index gained 0.35% to 25,408.85.
Among the pharma stocks, Biocon (up 2.10%), Sun Pharma (up 1.74%), Piramal Pharma (up 1.27%), Torrent Pharma (up 1.13%), Dr Reddys Labs (up 1.08%), Zydus Life (up 0.79%), Cipla (up 0.76%), Mankind Pharma (up 0.74%) and Glan Pharma (up 0.60%) advanced.
In her latest Budget speech, the FM said that the BioPharma Strategy for Health Advancement through knowledge, technology and innovation will strengthen India’s digital ecosystem in healthcare.
“India's digital disease burden is observed to be shifting towards non-communicable diseases like diabetes, cancer and autoimmune disorders.
Biologic medicines are key to longevity and quality of life at affordable costs. To develop India as a global biopharma manufacturing hub, I proposed the Biopharma Shakti with an outlay of Rs 10,000 crores over the next five years. This will build the ecosystem.
For domestic production of biologics and biosimilars, the strategy will include a biopharma-focused network with three new national institutes of pharmaceutical education and research, popularly known as NIPERS, and upgrading seven existing ones.
It will also create a network of 1,000 accredited India clinical trials sites. We propose to strengthen the Central Drug Standard Control Organisation to meet global standards and approve timeframes through a dedicated scientific review and specialists,” the FM said.